Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research Article
  • Published:

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias

Molecular Psychiatry volume 8, pages 343–347 (2003)Cite this article

Abstract

Early clinical symptoms of sporadic Creutzfeldt–Jakob disease (CJD) may overlap with other neurodegenerative diseases like Alzheimer's disease (AD) and frontotemporal degeneration (FTD). On entering an era in which pharmaceutical treatment of CJD occurs, reliable diagnostic markers like immunodetection of 14–3–3 proteins in the cerebrospinal fluid (CSF) are required. However, false negative results in autopsy-proven, sporadic CJD cases, as well as false positive results in several other disorders including AD and FTD showing high CSF tau protein levels, limit the potential of this marker. Due to neuronal lysis the cytosolic fraction of total tau containing phosphorylated and non-phosphorylated isoforms is partially liberated into the CSF. Since hyperphosphorylation of tau may specifically occur in neurodegenerative diseases associated with neurofibrillary changes, we hypothesized that the phospho-tau (P-tau)/total tau ratio in CSF may be a useful marker to discriminate CJD from other neurodegenerative disorders. The P-tau/total tau ratio discriminated patients with CJD from all other neuro-degenerative disorders including patients with AD and FTD without any overlap. Although the results have to be confirmed in a larger sample, the preliminary data suggest that simultaneous measurement of total tau and P-tau in CSF may be useful to identify patients with CJD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Hsich G, Kenney K, Gibbs C, Lee KH, Harrington MG . The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996; 335: 924–930.

    Article  CAS  Google Scholar 

  2. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RSG et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811–815.

    Article  CAS  Google Scholar 

  3. Burkhard P, Sanchez J-C, Landis T, Hochstrasser DF . CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001; 56: 1528–1533.

    Article  CAS  Google Scholar 

  4. Iqbal K, Grundke-Iqbal I . Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol Psychiatry 1997; 2: 178–180.

    Article  CAS  Google Scholar 

  5. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J et al. Elevated levels of Tau protein in CSF of patients with Creutzfeldt–Jakob disease. Neurosci Lett 1997; 225: 210–212.

    Article  CAS  Google Scholar 

  6. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP et al. Improved discrimination of Alzheimer's disease patients using beta-amyloid (1–42) and tau levels in CSF. Neurology 1999; 52: 1555–1562.

    Article  CAS  Google Scholar 

  7. Green A, Harvey R, Thompson E, Rossor MN . Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci Lett 1999; 259: 133–135.

    Article  CAS  Google Scholar 

  8. McKhann G, Folstein M, Katzman R, Price D, Stadlan EM . Clinical diagnosis of Alzheimer's disease. Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939–944.

    Article  CAS  Google Scholar 

  9. Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546–1554.

    Article  CAS  Google Scholar 

  10. Will R, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E et al. Descriptive epidemiology of Creutzfeldt–Jakob disease in six European countries, 1993–1995. EU collaborative study group for CJD. Ann Neurol 1998; 43: 763–767.

    Article  CAS  Google Scholar 

  11. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44: 609–614.

    Article  CAS  Google Scholar 

  12. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjögren M et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49–52.

    Article  CAS  Google Scholar 

  13. Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin JJ et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828–1834.

    Article  CAS  Google Scholar 

  14. Herrmann M, Golombowski S, Kräuchi K, Frey P, Mourton-Gilles C, Hulette C et al. ELISA-quantitation of phosphorylated tau protein in the Alzheimer's disease brain. Eur Neurol 1999; 42: 205–210.

    Article  CAS  Google Scholar 

  15. Hutton M, Lendon C, Rizzu P, Baker M, Froelich S, Houlden H et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702–705.

    Article  CAS  Google Scholar 

  16. Mann D, McDonagh A, Snowden J, Neary D, Pickering-Brown SM . Molecular classification of the dementias. Lancet 2000; 355: 626.

    Article  CAS  Google Scholar 

  17. Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 70: 624–630.

    Article  Google Scholar 

  18. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001; 297: 187–190.

    Article  CAS  Google Scholar 

  19. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, De Bernadis J et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 2000; 287: 187–190.

    Article  CAS  Google Scholar 

  20. Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999; 270: 91–94.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Neurochemistry and Neurogenetics Laboratory, Technische Universität München, Germany

    M Riemenschneider

  2. Institute of Medical Statistics and Epidemiology, Technische Universität München, Germany

    S Wagenpfeil

  3. Innogenetics NV, Ghent, Belgium

    H Vanderstichele & E Vanmechelen

  4. Department of Neurology, Universität Göttingen, Germany

    M Otto

  5. Department of Psychiatry, Universität Göttingen, Germany

    J Wiltfang

  6. Institute of Neuropathology, Ludwig Maximilians Universität, München, Germany

    H Kretzschmar

  7. Department of Psychiatry and Psychotherapy, Technische Universität München, Germany

    H Förstl & A Kurz

Authors
  1. M Riemenschneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Wagenpfeil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Vanderstichele
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Wiltfang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Kretzschmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Vanmechelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Förstl
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Kurz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Riemenschneider.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riemenschneider, M., Wagenpfeil, S., Vanderstichele, H. et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias. Mol Psychiatry 8, 343–347 (2003). https://doi.org/10.1038/sj.mp.4001220

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4001220

Keywords

This article is cited by

Search

Advanced search

Quick links